Insights
Search Results
Client Highlights
4.27.26
Wilson Sonsini Advises Nervonik on $52.5 Million Series B Financing
On April 27, 2026, Nervonik, a clinical-stage medical device company developing next-generation peripheral nerve stimulation (PNS) technologies, announced the closing of an oversubscribed $52.5 million Series B financing. The round was led by Amzak Health, with participation from Elevage Medical Technologies, U.S. Venture Partners (USVP), Lumira Ventures, Foothill Ventures, and Shangbay Capital. The proceeds from the financing will support the continued development and commercialization of Nervonik's PNS system, including further development of its proprietary sensing capabilities. Wilson Sonsini Goodrich & Rosati advised Nervonik on the transaction.
Client Highlights
3.25.26
Wilson Sonsini Advises Nosis Bio on Strategic Collaboration and License Agreement with Johnson & Johnson
On March 24, 2026, Nosis Bio, a pioneer in AI-enabled cell-specific delivery for RNA medicines, announced an expansion of its strategic collaboration with Johnson & Johnson. Their initial collaboration has been expanded through an option exercise, and simultaneously, Nosis Bio and Johnson & Johnson have entered into a new strategic collaboration agreement focused on neurology. The collaborations will deploy Nosis’ Connexa™ platform, which combines a proprietary atlas of cell-specific internalizing receptor targets with physics-aware generative AI, to design delivery vehicles that can navigate complex cell types. Wilson Sonsini Goodrich & Rosati advised Nosis Bio on the transaction.
Client Highlights
2.06.26
Wilson Sonsini Advises PacBio on Sale of Short-Read DNA Sequencing Assets
On February 2, 2026, PacBio, a leading developer of high-quality, highly accurate sequencing solutions, announced the completion of the sale of select intellectual property and other assets related to PacBio’s short-read DNA sequencing technology and related clustering, sequencing reagent, and detection technologies to Illumina, Inc. PacBio received approximately $50 million in cash proceeds from the transaction. Wilson Sonsini Goodrich & Rosati advised PacBio on the transaction.
Client Highlights
2.21.25
Wilson Sonsini Advises Anaerobe Systems on Acquisition by Biolog
On February 12, 2025, Biolog, a leading provider of cell-based microbial and phenotypic profiling products and multiomic microbial identification services, announced the acquisition of Anaerobe Systems. The acquisition will be funded through a financing led by J.P. Morgan Life Sciences Private Capital with participation from existing investors BroadOak Capital Partners and Research Corporation Technologies. Wilson Sonsini Goodrich & Rosati advised Anaerobe Systems on the transaction.
Client Highlights
3.21.24
Wilson Sonsini Advises LENZ Therapeutics on Completed Merger with Graphite Bio
On March 21, 2024, LENZ Therapeutics, Inc., a late clinical-stage biopharmaceutical company focused on developing the first aceclidine-based eye drop that has been shown to improve near vision in people with presbyopia, announced the completion of its previously announced merger with Graphite Bio, Inc. The new combined company will operate under the name LENZ Therapeutics, Inc. and will commence trading on Nasdaq under the ticker symbol “LENZ” on March 22, 2024. Wilson Sonsini Goodrich & Rosati advised LENZ Therapeutics on the transaction.
Client Highlights
11.15.23
Wilson Sonsini Represents LENZ Therapeutics in Merger with Graphite Bio
On November 15, 2023, LENZ Therapeutics, a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies to improve vision, and Graphite Bio, Inc. announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The lead programs of the combined company will address presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over the age of 45. The combined company is expected to trade on Nasdaq under the ticker symbol “LENZ.” Wilson Sonsini Goodrich & Rosati is representing LENZ Therapeutics in the transaction.
Client Highlights
10.24.23
Firm Advises Assembly Biosciences on Partnership with Gilead Sciences
On October 17, 2023, Gilead Sciences and Assembly Biosciences, a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, announced that they have entered into a 12-year partnership to advance the research and development of novel antiviral therapies, with an initial focus on Assembly Bio’s established areas of herpesviruses, hepatitis B virus (HBV), and hepatitis D virus (HDV). Wilson Sonsini Goodrich & Rosati advised Assembly Bio on the transaction.
Assembly Bio’s current portfolio of small molecule antiviral therapeutics includes both clinical and preclinical programs, including next-generation core inhibitor ABI-4334 for the treatment of HBV, long-acting helicase-primase inhibitor ABI-5366 for herpes simplex virus (HSV), an orally bioavailable HDV entry inhibitor ABI-6250, and a pan-herpes polymerase inhibitor program.
Assembly Bio’s current portfolio of small molecule antiviral therapeutics includes both clinical and preclinical programs, including next-generation core inhibitor ABI-4334 for the treatment of HBV, long-acting helicase-primase inhibitor ABI-5366 for herpes simplex virus (HSV), an orally bioavailable HDV entry inhibitor ABI-6250, and a pan-herpes polymerase inhibitor program.
Client Highlights
8.03.23
Wilson Sonsini Advises PacBio on Apton Biosystems Acquisition
On August 2, 2023, Pacific Biosciences of California (PacBio), a leading provider of high-quality, long-read sequencing platforms, announced that it has signed a definitive merger agreement to acquire Apton Biosystems, Inc. (Apton), a Bay-Area-based company developing a high throughput short-read sequencer using state-of-the-art optics and image processing, paired with novel clustering and chemistry, that is designed to enable the sequencing of billions of clusters of DNA on one flow cell. Wilson Sonsini Goodrich & Rosati is representing PacBio in the transaction.
Client Highlights
3.07.23
Wilson Sonsini Advises LENZ Therapeutics on $83.5 Million Series B Financing
On March 7, biopharmaceutical company LENZ Therapeutics announced that it raised $83.5 million in an oversubscribed Series B financing. The financing was led by new investor Sectoral Asset Management alongside Alpha Wave Ventures and Point 72. Existing investors RA Capital Management, Versant Ventures, RTW Investments, and others also participated. Wilson Sonsini Goodrich & Rosati represented LENZ in the transaction.
Client Highlights
3.02.23
Wilson Sonsini Advises CARGO Therapeutics on Series A Financing
On March 1, 2023, CARGO Therapeutics, Inc. (CARGO), a biotechnology company advancing a next generation of CAR T-cell therapies for cancer, announced the close of a $200 million oversubscribed and upsized Series A financing. The financing was co-led by Third Rock Ventures, RTW Investments, LP, and Perceptive Xontogeny Venture Fund, and includes additional new investors Nextech, Janus Henderson Investors, Ally Bridge Group, Wellington Management, funds and accounts advised by T. Rowe Price Associates, Inc., Cormorant Asset Management, and Piper Heartland. Founding investor Samsara BioCapital and existing seed investors Red Tree Venture Capital and Emerson Collective also participated in the financing.
Client Highlights
7.08.22
Wilson Sonsini Advises Matchwell on Its Acquisition by Medical Solutions
On July 6, 2022, Medical Solutions, one of the nation's largest providers of total workforce solutions serving the healthcare industry, announced it has acquired Durhan, North Carolina-based Matchwell. Matchwell’s AI enabled marketplace and SaaS solution efficiently matches licensed and certified staff with healthcare organizations across a variety of clinical settings ranging from hospitals to skilled and assisted living facilities, home health, clinics, and schools. Matchwell’s business model of subscription-based, per diem, and local services expands Medical Solutions’ current portfolio of service offerings into the per diem and local markets and further bolsters the company’s total workforce solutions model. Terms of the deal were not disclosed.
Client Highlights
4.14.22
Wilson Sonsini Advises Sierra Oncology on $1.9 Billion Acquisition by GSK
On April 13, 2022, GlaxoSmithKline plc (GSK) and Sierra Oncology, Inc. announced that they have entered into an agreement under which GSK will acquire Sierra Oncology, a late-stage biopharmaceutical company focused on targeted therapies for the treatment of rare forms of cancer, for $55 per share of common stock in cash, representing an approximate total equity value of $1.9 billion. The per-share price represents a premium of approximately 39 percent to Sierra Oncology’s closing stock price on April 12, 2022, and a premium of approximately 63 percent to Sierra Oncology’s VWAP over the last 30 trading days. Wilson Sonsini Goodrich & Rosati advised Sierra Oncology on the transaction.
Sierra Oncology’s differentiated momelotinib has the potential to address the critical unmet medical needs of myelofibrosis patients with anaemia. In January 2022, Sierra Oncology announced positive topline results from the MOMENTUM phase III trial. The study met all its primary and key secondary endpoints, demonstrating that momelotinib achieved a statistically significant and clinically meaningful benefit on symptoms, splenic response, and anemia. Sierra Oncology is anticipating U.S. regulatory submission in Q2 of this year and EU submission in the second half of 2022.
Wilson Sonsini has also advised Sierra Oncology on a number of recent financing transactions, including public warrant and equity issuances.
Sierra Oncology’s differentiated momelotinib has the potential to address the critical unmet medical needs of myelofibrosis patients with anaemia. In January 2022, Sierra Oncology announced positive topline results from the MOMENTUM phase III trial. The study met all its primary and key secondary endpoints, demonstrating that momelotinib achieved a statistically significant and clinically meaningful benefit on symptoms, splenic response, and anemia. Sierra Oncology is anticipating U.S. regulatory submission in Q2 of this year and EU submission in the second half of 2022.
Wilson Sonsini has also advised Sierra Oncology on a number of recent financing transactions, including public warrant and equity issuances.